TOVX Insider Trading Activity and SEC Form 4 Filings
TOVX insider trading summary
No open-market insider purchases or sales of Theriva Biologics, Inc. (TOVX) have been reported on SEC Form 4 in the past 12 months.
Latest TOVX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 7, 2023 | Steven A Shallcross | CEO and CFO | Buy | $10K (14,000 @ $0.69) |
| Jun 6, 2023 | Steven A Shallcross | CEO and CFO | Buy | $16K (26,000 @ $0.63) |
| Feb 10, 2023 | Steven A Shallcross | CEO and CFO | Buy | $26K (25,000 @ $1.04) |
| Feb 2, 2023 | Steven A Shallcross | CEO and CFO | Buy | $24K (25,000 @ $0.94) |
| Jan 25, 2023 | Steven A Shallcross | CEO and CFO | Buy | $22K (25,000 @ $0.87) |
| Jan 20, 2023 | Steven A Shallcross | CEO and CFO | Buy | $19K (25,000 @ $0.75) |
| Dec 29, 2022 | Steven A Shallcross | CEO and CFO | Buy | $44K (100,000 @ $0.44) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.